Answers are grounded in this paper and cite their sources.
Analysis demonstrates cost and complication differences in robotic-assisted and laparoscopic partial nephrectomy for renal cancer patients, suggesting minimally invasive techniques may offer benefits.
Partial nephrectomy is increasingly favored for small renal masses due to its renal function-preserving benefits. This study compared contemporary utilization patterns, perioperative outcomes, and hospital costs of robotic-assisted (RAPN), laparoscopic (LAPN), and open partial nephrectomy (OPN) among U.S. patients with renal cancer. Using the 2016–2019 National Inpatient Sample, renal cancer patients undergoing RAPN, LAPN, or OPN based on ICD-10-CM/PCS codes were identified. Patient demographics, comorbidities, hospital characteristics, length of stay (LOS), perioperative complications, and hospital costs, were summarized by surgical approach. Regression analyses adjusted for patient- and hospital-level covariates were used to compare perioperative outcomes, LOS, and costs across procedures. An estimated 89,290 partial nephrectomies were identified (mean age 59.4 years; 60.4% male; 68.9% white). RAPN was the most common approach (63.4%), followed by OPN (22.6%) and LAPN (14.0%). Median hospital costs were lowest for LAPN ($14,627), compared with RAPN ($15,187) and OPN ($15,364). Both RAPN and LAPN were associated with lower odds of perioperative complications compared with OPN (RAPN: OR 0.48, 95% CI 0.43–0.55; LAPN: OR 0.51, 95% CI 0.43–0.61). RAPN was additionally associated with lower odds of blood transfusion, in-hospital mortality, and shorter LOS. After adjustment, hospital costs for RAPN and LAPN were not statistically significantly different from those for OPN. RAPN represents the predominant minimally invasive approach for partial nephrectomy in contemporary U.S. practice. Minimally invasive techniques offer clear clinical advantages over open surgery, with RAPN demonstrating more favorable intraoperative outcomes than LAPN. Future research should assess long-term functional, oncologic, and economic outcomes.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: